EBUS-TBNA for Diagnosis of Mediastinal Lymphadenopathy

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01493739

Enrollment

100

Registered

2011-12-16

Start date

2009-01-31

Completion date

2012-01-31

Last updated

2011-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer, Mediastinal Lymphadenopathy

Brief summary

This study aims on the combinatorial results of cytology, histopathology and microbiology obatined by EBUS-TBNA for unselected mediastina lesions.

Detailed description

A number of studies have proved EBUS-TBNA to be useful for lymph node staging in lung cancer. The diagnostic performance is equivalent to mediastinoscopy while the invasiveness is far less. This study primarily focusing on merged approach of cytology, histopathology and microbioloogy obatined by EBUS-TBNA for unselected mediastina lesions.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Age \> 18 years old * mediastinal lymphadenopathy on Chest CT scan * with a short-axis \> 10mm

Exclusion criteria

* patients intolerant to bronchoscopy exam * unstable vital sign (Blood pressure, heart rate, breath rate)

Design outcomes

Primary

Measure	Time frame
Diagnostic rate	Participant will be followed within an average of three months

Countries

Taiwan

Contacts

Primary ContactChih-Hsi Kuo, MD

chihhsikuo@gmail.com

Backup ContactFu-Tsai Chung, MD

Outcome results